Combined treatment for soft tissue sarcoma using radiation therapy and surgery

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial involves a three-step treatment approach for patients with soft tissue sarcoma. Initially, patients receive preoperative stereotactic radiation therapy in a hypofractionation mode, followed by surgery 14-21 days later. After surgery, postoperative conformal radiation therapy is administered according to standard protocols. The radiation therapy plans are meticulously designed using MRI and CT scans to ensure precise targeting of the tumor and surrounding tissues.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* morphologically verified diagnosis of soft tissue sarcoma
* first diagnosed tumor process
* ability to perform radical surgery
* signed informed consent
* indications for stereotactic and conformal radiation therapy
* no contraindications for radiation and surgical treatment

Exclusion Criteria:

* previous radiation treatment
* acute infection
* pregnancy, lactation
* recurrent tumor
* refuse to sign informed consent
* conditions that can affect the outcome of treatment (immunodeficiency, tuberculosis, etc.)
* tumor topography and volume that don't allow to perform stereotactic and conformal radiation therapy.

Where it's running

• National Research Center of Oncology named after N.N.Petrov
  Saint Petersburg, Russia Recruiting

Study contacts

• Study coordinator: Grigory Zinovev, PhD
• Email: zinovevgrigory@gmail.com
• Phone: +79213405814

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Moderately Hypofractionated Neoadjuvant Radiotherapy for Soft Tissue Sarcoma of the Limbs or Trunk Wall

  This trial tests whether giving a shorter course of radiotherapy before surgery helps control soft tissue sarcoma in the limbs or trunk without waiting longer.

  Recruiting Phase 2 Centre Oscar Lambret · Lille · NCT07507773

• Personalised neoadjuvant therapy planning for adults with high‑risk soft tissue sarcoma

  This project tests whether analyzing tumor tissue and clinical data can help guide neoadjuvant chemotherapy decisions for adults with high‑risk soft tissue sarcomas.

  Recruiting Royal Marsden NHS Foundation Trust · London · NCT07432932

• Dose‑escalated, short‑course proton radiation for inoperable soft tissue sarcoma

  This will try higher-dose, shorter-course proton radiation to see if it controls tumors better in adults with inoperable soft tissue sarcoma.

  Recruiting Phase 2 Oslo University Hospital · Bergen and 1 other locations · NCT07173972

• Three-week preoperative proton versus X-ray radiotherapy for localized soft tissue sarcoma

  This trial tests whether selecting proton rather than standard X‑ray radiotherapy before surgery for adults with localized soft tissue sarcoma can lower long-term radiation side effects without increasing surgical complications.

  Recruiting Phase 2 Oslo University Hospital · Bergen and 3 other locations · NCT07169344

• Tiny, direct injections of PBA-0111 into solid tumors to see local immune and tumor responses

  This study will try tiny, localized injections of PBA-0111 into tumors of adults with head and neck cancer, selected soft-tissue sarcomas, or triple-negative breast cancer to see if it triggers immune activity and tumor cell killing in the tumor microenvironment.

  Recruiting Early Phase 1 Pure Biologics S.A. · Shreveport, Louisiana · NCT06700070

• Combining propranolol and pembrolizumab for advanced soft tissue sarcoma

  This study is testing a new combination of two medications, propranolol and pembrolizumab, to see if it can help people with advanced angiosarcoma or undifferentiated pleomorphic sarcoma live longer and feel better.

  Recruiting at 2 sites Phase 2 Herlev and Gentofte Hospital · Aarhus and 3 other locations · NCT05961761

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.